(Q37777495)

23 August 2017

1 reference

title

Safety considerations for use of bone-targeted agents in patients with cancer (English)

1 reference

23 August 2017

Safety Considerations for Use of Bone-Targeted Agents in Patients With Cancer (English)

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

16 June 2024

1

Joanne E. Mortimer

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A20682374

16 June 2024

author name string

Sumanta Kumar Pal

2

1 reference

23 August 2017

language of work or name

English

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=20682374

16 June 2024

publication date

1 June 2010

1 reference

full work available at URL

23 August 2017

https://api.elsevier.com/content/article/PII:S0093775410000850?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

https://api.elsevier.com/content/article/PII:S0093775410000850?httpAccept=text/plain

16 June 2024

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

16 June 2024

1 reference

23 August 2017

volume

37 Suppl 1

1 reference

23 August 2017

page(s)

S66-72

1 reference

Metastatic bone disease: clinical features, pathophysiology and treatment strategies

23 August 2017

cites work

2

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Metastasis to bone: causes, consequences and therapeutic opportunities

16 June 2024

3

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel

16 June 2024

4

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

American Society of Clinical Oncology guideline on the role of bisphosphonates in breast cancer. American Society of Clinical Oncology Bisphosphonates Expert Panel

16 June 2024

7

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Role of bisphosphonates in prostate cancer

16 June 2024

8

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Bisphosphonates as adjuvant therapy for breast cancer

16 June 2024

10

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

16 June 2024

11

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Bisphosphonate-related osteonecrosis of the jaw: diagnosis, prevention, and management

16 June 2024

13

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Management of the adverse effects associated with intravenous bisphosphonates

16 June 2024

14

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial

16 June 2024

15

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial

16 June 2024

16

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

16 June 2024

17

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer

16 June 2024

18

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.

16 June 2024

19

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Zoledronic acid in the treatment of hypercalcemia of malignancy: results of the international clinical development program

16 June 2024

20

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy

16 June 2024

21

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Renal safety of ibandronate

16 June 2024

22

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Bisphosphonate nephrotoxicity

16 June 2024

23

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Bisphosphonate-associated osteonecrosis: a long-term complication of bisphosphonate treatment

16 June 2024

24

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Osteonecrosis of the jaw in multiple myeloma patients: clinical features and risk factors.

16 June 2024

25

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

16 June 2024

26

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Consensus practice guidelines for bisphosphonate-associated osteonecrosis of the jaw

16 June 2024

27

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Frequency and risk factors associated with osteonecrosis of the jaw in cancer patients treated with intravenous bisphosphonates

16 June 2024

28

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan.

16 June 2024

29

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Zoledronic acid effectively prevents aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole: Z-FAST study 36-month follow-up results.

16 June 2024

31

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

The effects of adding zoledronic acid to neoadjuvant chemotherapy on tumour response: exploratory evidence for direct anti-tumour activity in breast cancer

16 June 2024

32

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial

16 June 2024

33

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer

16 June 2024

34

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

The impact of zoledronic acid therapy in survival of lung cancer patients with bone metastasis.

16 June 2024

35

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women

16 June 2024

36

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

16 June 2024

37

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer

16 June 2024

38

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Effects of denosumab on bone mineral density and bone turnover in postmenopausal women

16 June 2024

39

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

16 June 2024

40

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

The relationship between plasma osteoprotegerin levels and coronary artery calcification in uncomplicated type 2 diabetic subjects

16 June 2024

41

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Regulation of vascular calcification by osteoclast regulatory factors RANKL and osteoprotegerin

16 June 2024

42

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Efficacy and safety of denosumab in postmenopausal women with osteopenia or osteoporosis: a systematic review and a meta-analysis.

16 June 2024

43

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesis

16 June 2024

44

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Receptor activator of NF-kappaB ligand enhances the activity of macrophages as antigen presenting cells

16 June 2024

45

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

TRANCE (tumor necrosis factor [TNF]-related activation-induced cytokine), a new TNF family member predominantly expressed in T cells, is a dendritic cell-specific survival factor

16 June 2024

46

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Pharmacovigilance and reporting oversight in US FDA fast-track process: bisphosphonates and osteonecrosis of the jaw.

16 June 2024

48

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients

16 June 2024

49

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours

16 June 2024

50

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients

16 June 2024

51

1 reference

https://api.crossref.org/works/10.1053/J.SEMINONCOL.2010.06.006

16 June 2024

Identifiers

1 reference

23 August 2017

1 reference